Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Maxwell Biosciences Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, indicating that the company's current applications involve different technical sub-specialties. This distribution requires the practitioner to navigate two separate examination paths within the patent office. The busiest examiner is SCOTLAND, REBECCA LYNN, who is handling 1 busiest examiner pending action.
Because the 2 pending office actions are assigned to 2 distinct examiners, the portfolio's current workload is distributed equally among the assigned personnel. This arrangement means that each application will be subject to the unique examination style of a different individual. Practitioners should be prepared to address the specific technical concerns of 2 distinct art units, as this variety suggests that the applications cover diverse aspects of the Biotechnology & Pharmaceuticals field. Managing the current docket requires a tailored approach for each pending matter to ensure effective communication with the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571992 | SUBSTRATES MODIFIED WITH PEPTOID-LOADED MICROGELS FOR RESISTANCE TO BACTERIAL COLONIZATION | SCOTLAND, REBECCA LYNN | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606761 | HALOGENATED ANTIMICROBIAL PEPTOIDS | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571992 | SUBSTRATES MODIFIED WITH PEPTOID-LOADED MICROGELS FOR RESISTANCE TO BACTERIAL COLONIZATION | SCOTLAND, REBECCA LYNN | 1615 | §103§112Other | Non-Final OA | 55d | Pending | Dec 19, 2023 |
| 17606761 | HALOGENATED ANTIMICROBIAL PEPTOIDS | REYNOLDS, FRED H | 1658 | §103 | Final Rejection | — | Pending | Oct 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial